Export as PDF
Cohort Acronym

Cohort type
Neurodegenerative disease-specific cohort

Alzheimer's disease, Mild cognitive impairment (MCI), Subjective memory complaints (SMC) or subjective cognitive decline (SCD)

Participant type
Condition diagnosed

Recruitment Period 2004 
Sample size at start or planned sample size if still recruiting 2200  
Estimated Current Sample Size 0 to 4,999 
Age at Recruitment >55   
Gender Male and Female 

ADNI began in October 2004. The overall goal is to validate biomarkers for Alzheimer’s disease clinical trials. One aim is to find, validate and standardize more sensitive and accurate methods to detect Alzheimer’s disease at earlier stages and mark its progress through biomarkers. The study gathered and analyzed thousands of brain scans, genetic profiles, and biomarkers in blood and cerebrospinal fluid that are used to measure the progress of disease or the effects of treatment. More information on ADNI-info.org. All data is publically available at USC/LONI/ADNI.

The three overarching longitudinal ADNI study goals are:

  • Validation of biomarkers, especially for amyloid and tau, for use in AD clinical trials.
  • To detect Alzheimer’s disease (AD) at the earliest stage possible and identify ways to track the disease through biomarkers.
  • To support advances in AD intervention, prevention and treatment through the application of new diagnostic methods to apply at the earliest stages technically possible – when intervention may be most effective.
  • To continually develop ADNI’s now- legendary data access policy and continuously improve and expand the unprecedented data sharing model.

Last update – 07/02/2017

Country Canada, USA 
Contact details
Institution name Northern California Institute for Research and Education 
Principal Investiator (PI) Michael W. Weiner MD 
Contact email [email protected] 
Contact phone number +11 31 415 750-2146 
Funders (Core support) National Institute on Aging,
National Institute of Health,
Foundation for NIH (FNIH) 

Variables Collected

Brain related measures: Behaviour, Cognitive function, Mental health
Funtional rating: Individual physiological, Individual psychological
Anthropometric: Blood pressure, Height, Weight
Physical: Hearing and Vision
Biological samples: Blood, Cerebral spinal fluid (CSF), CSF biomarker data available, Other, Urine
Genotyping: Gene screening
Brain imaging: Magnetic resonance imaging (MRI), Positron emission tomography (PET) - amyloid, Positron emission tomography (PET) fluorine18 flurodeoxyglucose (FDG)
Brain banking: Consent for brain donation
Lifestyle: Smoking
Socio-economic: Education, Ethnic group, Family circumstances, Marital status
Health service utilisation: N/A
Export as PDF